Healthy Adults

17
Pipeline Programs
7
Companies
17
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
17
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
5 programs
5
PF-07104091Phase 11 trial
PF-07220060Phase 11 trial
PF-07248144Phase 11 trial
PF-07248144Phase 11 trial
PF-08049820Phase 11 trial
Active Trials
NCT07127770Completed9Est. Nov 2025
NCT06897683Completed14Est. Jun 2025
NCT07198035Recruiting12Est. Dec 2025
+2 more trials
Tonix Pharmaceuticals
Tonix PharmaceuticalsBERKELEY HEIGHTS, NJ
4 programs
4
SL TNX-102 2.4 mg at pH 3.5Phase 11 trial
SL TNX-102 at 2.4 mgPhase 11 trial
TNX-102 SL Tablets at 2.8 mgPhase 11 trial
Treatment APhase 11 trial
Active Trials
NCT01634412Completed24Est. Jan 2014
NCT01689259Completed24Est. Mar 2014
NCT01889173Completed24Est. Mar 2014
+1 more trials
Corcept Therapeutics
Corcept TherapeuticsCA - Redwood City
3 programs
3
CORT113176Phase 11 trial
CORT113176 Lipid Capsule FormulationPhase 11 trial
DazucorilantPhase 11 trial
Active Trials
NCT04994743Completed16Est. Sep 2021
NCT04249323Completed110Est. Oct 2020
NCT06495944Completed21Est. Aug 2024
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
2 programs
2
SC MethylnaltrexonePhase 11 trial
methylnaltrexonePhase 11 trial
Active Trials
NCT01367535CompletedEst. Aug 2006
NCT01366365CompletedEst. Nov 2006
Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
BMS-986089Phase 11 trial
Active Trials
NCT02145234Completed140Est. Feb 2016
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
1
Bismuth subsalicylatePhase 11 trial
Active Trials
NCT05930197CompletedEst. Dec 2024
Edgewise Therapeutics
1 program
1
EDG-15400Phase 11 trial
Active Trials
NCT07177066Recruiting108Est. May 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PfizerPF-08049820
PfizerPF-07248144
PfizerPF-07104091
Edgewise TherapeuticsEDG-15400
PfizerPF-07220060
PfizerPF-07248144
Corcept TherapeuticsDazucorilant
Allergy TherapeuticsBismuth subsalicylate
Corcept TherapeuticsCORT113176
Corcept TherapeuticsCORT113176 Lipid Capsule Formulation
Tonix PharmaceuticalsTreatment A
RocheBMS-986089
Tonix PharmaceuticalsTNX-102 SL Tablets at 2.8 mg
Tonix PharmaceuticalsSL TNX-102 at 2.4 mg
Tonix PharmaceuticalsSL TNX-102 2.4 mg at pH 3.5

Showing 15 of 17 trials with date data

Clinical Trials (17)

Total enrollment: 587 patients across 17 trials

A Study to Learn if a Medicine That Reduces Stomach Acid Affects the Blood Level of Study Medicine PF-08049820 in Healthy Chinese Adults.

Start: Nov 2025Est. completion: Dec 202518 patients
Phase 1Active Not Recruiting

A Study to Learn if Multiple Doses of the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine PF-07248144

Start: Sep 2025Est. completion: Dec 202512 patients
Phase 1Recruiting

A Study to Understand How the Body Processes [14C]PF-07104091 in Healthy Participants

Start: Aug 2025Est. completion: Nov 20259 patients
Phase 1Completed

A Study of EDG-15400 in Healthy Adults

Start: Aug 2025Est. completion: May 2026108 patients
Phase 1Recruiting

A Study to Learn if the Study Medicine Called Carbamazepine Changes How the Body Processes PF-07220060

Start: Mar 2025Est. completion: Jun 202514 patients
Phase 1Completed

A Study to Learn About How Different Forms of Study Medicine PF-07248144 Are Taken Up Into the Blood in Healthy Adults

Start: Feb 2025Est. completion: Jul 202524 patients
Phase 1Completed

Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants

Start: May 2024Est. completion: Aug 202421 patients
Phase 1Completed
NCT05930197Allergy TherapeuticsBismuth subsalicylate

Effect of Bismuth Subsalicylate on the Gut Microbiome and Host Response in Healthy Adults

Start: Aug 2023Est. completion: Dec 2024
Phase 1Completed

Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy Participants

Start: Jul 2021Est. completion: Sep 202116 patients
Phase 1Completed
NCT04249323Corcept TherapeuticsCORT113176 Lipid Capsule Formulation

Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants

Start: Jan 2020Est. completion: Oct 2020110 patients
Phase 1Completed

Bioequivalence Study of TNX-102 SL 2.8 mg Sublingual Tablets From Two Manufacturers.

Start: Dec 2015Est. completion: Jan 201643 patients
Phase 1Completed

Placebo-Controlled, Single and Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986089 in Healthy Adult Subjects

Start: Jun 2014Est. completion: Feb 2016140 patients
Phase 1Completed
NCT01889173Tonix PharmaceuticalsTNX-102 SL Tablets at 2.8 mg

Comparative Pharmacokinetics and Safety of 3 Different Formulations of TNX-102 2.8 mg SL Tablets and Cyclobenzaprine 5 mg Oral Tablet in Healthy Adults

Start: Jun 2013Est. completion: Mar 201424 patients
Phase 1Completed

Comparative Pharmacokinetics and Safety of TNX-102 SL Tablets and Cyclobenzaprine Oral Tablet in Healthy Adults

Start: Sep 2012Est. completion: Mar 201424 patients
Phase 1Completed
NCT01634412Tonix PharmaceuticalsSL TNX-102 2.4 mg at pH 3.5

Comparative Bioavailability of Sublingual TNX-102, Oral and Intravenous Cyclobenzaprine in Healthy Adults

Start: Jun 2012Est. completion: Jan 201424 patients
Phase 1Completed
NCT01366365Bausch Healthmethylnaltrexone

Study of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrexone Bromide

Start: Oct 2006Est. completion: Nov 2006
Phase 1Completed
NCT01367535Bausch HealthSC Methylnaltrexone

Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan

Start: Mar 2006Est. completion: Aug 2006
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 587 patients
7 companies competing in this space